Functional responses to the cannabinoid agonist WIN 55,212-2 in neonatal rats of both genders: influence of weaning.
We have studied behavioural, biochemical and endocrine responses to the cannabinoid agonist WIN 55,212-2 (WIN) in neonatal rats, as well as the effects of weaning on such responses. We used preweanling rats (20 days of age), 25-day-old weaned rats (weaning at Day 22) and 25-day-old nonweaned rats of both sexes. The behavioural effects of WIN were assessed in the nociceptive tail immersion test and in the open field. We also analysed the effect of weaning on corticosterone responses to WIN (radioimmunoassay) as well as on WIN-stimulated [35S] GTPgammaS binding in periaqueductal grey (PAG) and striatum. The cannabinoid agonist induced a modest increase in pain thresholds, whereas the effect of the drug on open-field activity, particularly on vertical activity, was much more marked. The weaning process appeared to reduce the baseline nociceptive latencies of the female rats. No significant effect of weaning on the behavioural responses to WIN was found. However, the group of weaned females (but not males) showed a significantly reduced WIN-stimulated [35S] GTPgammaS binding in the striatum. The cannabinoid agonist significantly increased the corticosterone levels of 25-day-old rats with the effect being more marked in weaned than in nonweaned animals. The results suggest that the weaning process might produce some sexually dimorphic developmental changes in CB1 receptor function.
Borcel
Erika
E
Departamento de Fisiología (Fisiología Animal II), Facultad de Ciencias Biológicas, Universidad Complutense, Ciudad Universitaria, C/Jose Antonio Novais, 2; 28040 Madrid, Spain.
Pérez-Alvarez
Laura
L
de Ceballos
María L
ML
Ramirez
Belén G
BG
Marco
Eva Maria
EM
Fernández
Beatriz
B
Rubio
Marina
M
Guaza
Carmen
C
Viveros
Ma-Paz
MP
D000818:Animals; D000831:Animals, Newborn; D048588:Benzoxazines; D003345:Corticosterone / Q000097:blood; D005260:Female; D006160:Guanosine Triphosphate / Q000031:analogs & derivatives* / Q000378:metabolism; D008297:Male; D009025:Morpholines / Q000494:pharmacology*; D009281:Naphthalenes / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000502:physiology; D012727:Sex Characteristics; D014886:Weaning
D048588:Benzoxazines; D009025:Morpholines; D009281:Naphthalenes; D043884:Receptor, Cannabinoid, CB1; C054439:guanosine 5'-(gamma-fluorotriphosphate); C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D006160:Guanosine Triphosphate; D003345:Corticosterone